Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA).

Full DD Report for VNDA

You must become a subscriber to view this report.


Recent News from (NASDAQ: VNDA)

Vanda Pharmaceuticals (VNDA) Presents At 43rd annual Deutsche Bank Healthcare Conference - Slideshow
The following slide deck was published by Vanda Pharmaceuticals Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 10 2018 15:09
Investor Expectations to Drive Momentum within Plains Group Holdings, EnteroMedics, Vanda Pharmaceuticals, Cinemark, EPR Properties, and The Estee Lauder Companies - Discovering Underlying Factors of Influence
NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Plains Group Holdings, L.P. (NYSE:PAGP), EnteroMedics Inc. (NASDAQ:RSLS), ...
Source: GlobeNewswire
Date: May, 10 2018 08:00
Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
WASHINGTON , May 7, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the Deutsche Bank 43 rd Annual Health Care Conference in Boston, Massachusetts on Wednesday, May 9, 2018 at 8:00 a.m. Eastern ...
Source: PR Newswire
Date: May, 07 2018 09:00
Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results - Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q1 2018 Earnings Conference Call May 02, 2018, 04:30 PM ET Executives Jim Kelly - EVP and CFO Mihael Polymeropoulos - President and CEO Analysts Corey Davis - Seaport Global Presentation Operator Hello and welcome to the Q1 2018, Va...
Source: SeekingAlpha
Date: May, 02 2018 22:32
Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results
WASHINGTON , May 2, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced financial and operational results for the first quarter ended March 31, 2018 . "We are pleased with the progress made in 2018 with the continued growth of our HETLIOZ bu...
Source: PR Newswire
Date: May, 02 2018 16:01
Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018
WASHINGTON , April 18, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2018 on Wednesday, May 2, 2018 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday ,...
Source: PR Newswire
Date: April, 18 2018 16:30
Vanda Wins Appeal Case on Fanapt®
WASHINGTON , April 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that West Ward Pharmaceu...
Source: PR Newswire
Date: April, 13 2018 12:00
Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis
WASHINGTON , April 9, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced participation at the 2018 Georg Rajka International Symposium of Atopic Dermatitis (ISAD 2018) in Utrecht, Netherlands in the scientific poster forum on Thursday, April 12, 2018...
Source: PR Newswire
Date: April, 09 2018 16:01
Your Daily Pharma Scoop: Aratana Earnings, Vanda Offering, Opko 4kscore Shows Benefit
Quick investment opinion: Aratana Therapeutics Aratana (NASDAQ: PETX ), which we covered in the early days of our Seeking Alpha work, released earnings this week. In our July 2017 article, we had said that although PETX is having trouble delivering drugs even after approval, its strong pip...
Source: SeekingAlpha
Date: March, 17 2018 08:00
Key events next week - healthcare
Noteworthy events for the week of March 18 - 24 for healthcare investors: More news on: Spark Therapeutics, SELLAS Life Sciences Group, Inc., Atara Biotherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 16 2018 10:25

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1717.0016.9017.1516.825362,975
2017-03-1015.0014.9515.0514.8565,517
2017-03-0915.0014.9015.22514.50542,516
2017-03-0814.2514.9515.0514.14879,262
2017-03-0714.3014.2014.5014.10327,778

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1520,078114,85917.4806Cover
2018-08-144,62238,77311.9207Cover
2018-08-137,04877,1459.1360Cover
2018-08-1019,75381,93124.1093Cover
2018-08-0916,32150,85132.0957Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VNDA.


About Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Logo for Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $867,643,172 - 05/11/2018
  • Issue and Outstanding: 52,110,701 - 04/19/2018

 


Recent Filings from (NASDAQ: VNDA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 16 2018

 

 


Daily Technical Chart for (NASDAQ: VNDA)

Daily Technical Chart for (NASDAQ: VNDA)


Stay tuned for daily updates and more on (NASDAQ: VNDA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: VNDA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VNDA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of VNDA and does not buy, sell, or trade any shares of VNDA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/